Abstract
Although the multi-state procedure with new chemical entities and generics appears to be in the process of being phased out, there are certain advantages that the multi-state procedure has over national registration. These components may be useful in any future European registration system. The effectiveness of multi-state procedures is illustrated with three examples: Theophylline, Salbutamol, and Urapidil.
Get full access to this article
View all access options for this article.